GEM （1250mg/m2)+tri-Her. GEM単剤（1250mg/m2).
JM8. Nealorin. Neocarbo. NSC … Paclitaxel Plus Carboplatin in Advanced Non–Small-Cell ... of the carboplatin (CBDCA) AUC on the efficacy and tolerance of the CBDCA, Taxol association (abstract 1712). Proc Am Soc Clin Oncol 16:475A, 1997. 20. Kosmidis PA, Mylonakis N, Skarlos D, et al: A multicenter randomized trial of paclitaxel (175 mg/m2) plus carboplatin (6 AUC) in advanced non small-cell lung cancer (abstract).
New Guidelines for Carboplatin Dosing | Memorial Sloan ...
Gemcitabine 800 mg/m 2 days 1,8 or 15 Untreated. 10. 33. A phase II study of combination therapy with liposomal ...
CBDCA-therapy had to be abandoned in 2 patients due to AUC 2 q1w). ( AUC = 6 on day1 every 3 weeks) and docetaxel (75 mg/m2 d1 every 3 weeks); 2.
No difference in the initial dosage of PTX (mg/m 2) or CBDCA (AUC) was observed between both groups. However, the obesity group had a higher initial CBDCA dosage (mg/body unit) and total CBDCA dosage after two courses (mg/body unit) than the control group .
cis-Diammine(cyclobutanedicarboxylato)platinum II. Ercar. JM 8. JM-8. JM8. Nealorin. Neocarbo. NSC … Paclitaxel Plus Carboplatin in Advanced Non–Small-Cell ... of the carboplatin (CBDCA) AUC on the efficacy and tolerance of the CBDCA, Taxol association (abstract 1712).
CBDCA area under the curve (AUC), and performance status were correlated with severe neutropenia and thrombocytopenia, but carboplatin AUC was the only in- dependent variable predictive of severity of both at multiple regression analysis. Thrombocytopenia was the major dose-limiting toxicity in this study. Atezolizumab in Combination With Carboplatin Plus ... May 16, 2018 · After completing 4 to 6 cycles of carboplatin plus pemetrexed and atezolizumab, patients will continue with pemetrexed in combination with atezolizumab until unacceptable toxicity, disease progression, patient/physician decision or completion of 2 years of therapy. [Full text] Feasibility Study of Adjuvant Chemotherapy ...
Advantages and disadvantages of Cisplatin or carboplatin in adjuvant chemotherapy of NSCLC . (80 mg/m 2, in the first cycle 60 mg/m 2). CDDP in dose of 80 mg/m 2 or CBDCA (AUC 5) were chosen individually according to center and patient preference. Results: In both SWITCH A multicenter phase II trial of paclitaxel, carboplatin ...
The administration of G‐CSF permits safe escalation of CBDCA dose and AUC up to 600 mg/m 2 and 8 respectively, in combination with a fixed dose of oral etoposide. Age older than 70 years represents a major obstacle to dose escalation. The increase of the body exposure to carboplatin seems to be associated with a better outcome. Definition of carboplatin - NCI Drug Dictionary - National ... The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials Investigation of tolerability and quality of life for ...
Preliminary Results of a Phase II Study of Weekly ... After completion of chemoradiotherapy, consolidation chemotherapy was administered via a 3-hour i.v.
NS. RR. NSCLC. 2. IIIb, IV ECOG 0-2. CDDP (80 mg/m2),. GEM (1000 mg/m2 (d. 1,8,15)).